Cannabis builds one precursor, CBGA, then splits it three ways using three competing enzymes. THCA synthase makes THCA. CBDA synthase makes CBDA. CBCA synthase makes CBCA.
CBD is what CBDA becomes when it loses a carbon dioxide group to heat and time.
CBG is what is left of CBGA when the synthases have not consumed it. This is why CBG is scarce in most cultivars and why CBG products cost more. It is a botany problem, not a potency signal.
CBN is not on that diagram at all. It has no synthase. It forms when THC sits in contact with oxygen, heat and light and degrades. High CBN means old or heat-treated material. Concentrated CBN products are made by deliberately degrading THC.
That last point deserves emphasis, because it is the honest answer to why the three are not really peers. Two are plant products. One is a decay product.
CBD does very little at cannabinoid receptors. The FDA’s Epidiolex label says outright that cannabidiol does not appear to exert its anticonvulsant effects through interaction with cannabinoid receptors. Its genuinely potent action is blocking the ENT1 adenosine transporter, below 250 nanomolar. It also hits TRPA1 hard, at 0.09 micromolar, and has activity at TRPV1, 5-HT1A and GPR55. A 2015 systematic review of over 65 reported CBD targets concluded most are only reached at concentrations people never achieve.
CBG has the single most potent number of the three. A 2010 study found alpha-2 adrenoceptor agonism at an EC50 of 0.2 nanomolar in mouse brain membranes. That is the receptor family clonidine acts on. The same paper found the effect much weaker in isolated tissue, so its physiological relevance is unresolved. CBG is also a 5-HT1A antagonist, which is the opposite direction to CBD at the same receptor.
CBN is a weak partial agonist at CB1, roughly 29 percent maximum effect against THC’s 72 percent. The more interesting finding is that its metabolite, 11-OH-CBN, reaches equivalent brain concentrations and behaves like THC at CB1. If CBN does anything centrally, that metabolite is probably responsible.
Notice that the compound with the most marketing energy behind it, CBN, has the weakest supporting result.
We are not able to recommend any of these for a health condition, and we would not want to. What we can do is set out what is actually known so the choice is yours to make with the facts visible.
If you want the most researched option, that is CBD, by a wide margin, though the research is not uniformly positive.
If you find the pharmacology interesting and accept the uncertainty, CBG has the most striking receptor number and one supportive small study.
If you are considering CBN for sleep, understand that the one human trial missed its primary endpoint and used a dose far above what is sold. That is worth knowing before you pay a premium for it.
Still weighing up the options? See CBG vs CBD, CBN vs CBD or CBG vs CBN. For more background, read our guide on CBD for sleep. Endoca products related to this comparison: CBN products.
All three have been treated as lawful under the 2018 Farm Bill when derived from hemp under 0.3 percent delta-9 THC by dry weight.
From 12 November 2026, Section 781 of Public Law 119-37 changes the test to total THC including THCA and excludes cannabinoids synthesized or manufactured outside the plant. CBN is the one to watch, because concentrated CBN is generally produced by converting THC rather than by extracting naturally occurring material. FDA has not published the cannabinoid lists the rule depends on, more than six months past its deadline. A Senate-passed one-month delay had not cleared the House as of 1 September 2026.
All three appear on every Endoca certificate of analysis, alongside CBDA, CBC, THC and THCA, tied to the batch code on your bottle. We publish the CBN number even when it is low, because low CBN in a CBD product means the material was extracted and stored well. Numbers on a lab report are the only claim about cannabinoid content that means anything.
They are commonly combined and no interaction problem is documented. There is no evidence that the combination outperforms any of them alone.
They are not on the same scale. CBG has the most potent single receptor number. CBD has the most human evidence. CBN is the only one that is weakly intoxicating at very high doses.
The plant converts nearly all of its CBGA into other cannabinoids. Harvesting CBG means sacrificing yield.
Usually a small amount, and it rises as the product ages.
Full-spectrum hemp extract typically contains CBD, CBDA, CBG, CBC and small amounts of CBN and THC. The certificate of analysis gives the actual figures.
None has strong human evidence for sleep. CBN is the one most marketed for sleep, and the trials so far are small with mixed results. CBD has more human research overall, but sleep was rarely the main outcome.
CBN forms when THC breaks down and is a weak CB1 agonist, far weaker than THC. At the amounts found in CBD and CBN products it is not considered intoxicating, though high isolated doses are less well studied.
Cascio MG et al. Cannabigerol is a highly potent alpha-2-adrenoceptor agonist. Br J Pharmacol 2010;159:129-141.
Cuttler C et al. Acute effects of cannabigerol on anxiety, stress and mood. Sci Rep 2024;14:16163.
Lavender I et al. The effects of cannabinol on sleep in insomnia disorder. J Sleep Res 2026;35:e70284.
Arnold JC et al. Cannabinol and its metabolite 11-OH-CBN. Neuropsychopharmacology 2025;50:586-595.
Ibeas Bih C et al. Molecular Targets of Cannabidiol. Neurotherapeutics 2015;12:699-730.
Moore RA et al. Cannabidiol (CBD) for Pain. J Pain 2024;25:833-842.
Finlay DB et al. Terpenoids From Cannabis Do Not Mediate an Entourage Effect. Front Pharmacol 2020;11:359.
Zagzoog A et al. Minor phytocannabinoid pharmacology. Sci Rep 2020;10:20405.
Last reviewed 1 September 2026.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.